Korea Accelerating Efforts To Develop, Launch Orphan Drugs
This article was originally published in PharmAsia News
South Korea is moving to speed up the development and launch of orphan drugs amid a growing need to ease medicine supply disruptions. Through revisions in rules, the government will make it easier to designate orphan drugs, which will undergo review 10 years after approval, rather than five years.
Register for our free email digests: